Long-term outcomes of nonpalpable prostate cancer (T1c) patients treated with radical prostatectomy

Center for cancer control and information services, National Cancer Center, Japan. Epstein, 2010, An update of the Gleason grading system, J Urol, 183, 433 Hung, 2002, Stage T1c prostate cancer : a heterogeneous category with widely varying prognosis, Cancer J, 8, 440, 10.1097/00130404-200211000-00007 Epstein, 1994, Radical prostatectomy for impalpable prostate cancer : the Johns Hopkins experience with tumors found on transurethral resection (stages T1A and T1B) and on needle biopsy (stage T1C), J Urol, 152, 1721 Epstein, 1998, Nonpalpable stage T1c prostate cancer : prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings, J Urol, 160, 2407 Lerner, 1996, Prostate specific antigen detected prostate cancer ( clinical stage T1c) : an interim analysis, J Urol, 155, 821 Hoedemaeker, 1997, Comparison of pathologic characteristics of T1c and non-T1c cancers detected in a population-based screening study, the European Randomized Study of Screening for prostate cancer, World J Urol, 15, 339, 10.1007/BF01300181 Shaw, 2014, Identification of pathologically insignificant prostate cancer is not accurate in unscreened men, Br J Cancer, 192, 1 Milonas, 2014, Evaluation of D'Amico criteria for low-risk prostate cancer, Scand J Urol, 10.3109/21681805.2013.870602 Carter, 1997, Preoperative evaluation of men with stage T1C adenocarcinoma of the prostate, J Urol, 157, 2206 Elgamal, 1996, Free-to-total prostate specific antigen ratio as a single test for detection of significant stage T1c prostate cancer cancer, J Urol, 156, 1042 Epstein, 1998, Nonpalpable stage T1c prostate cancer : prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings, J Urol, 169, 2407 Steyerberg, 2007, Prediction of indolent prostate cancer : validation and updating of a prognostic nomogram, J Urol, 177, 107 Iremashvili, 2013, Comparative validation of nomograms predicting clinically insignificant prostate cancer, Urology, 81, 1202, 10.1016/j.urology.2013.01.062 Kakehi, 2000, Clinical significance of nonpalpable prostate cancer with favorable biopsy features in Japanese men, Eur Urol, 37, 552, 10.1159/000020192 Ohori, 2003, Do impalpable stage T1c prostate cancers visible on ultrasound differ from those not visible?, J Urol, 169, 964 Boyce, 2013, Evaluation of prediction models for the staging of prostate cancer, BMC Med Inform Decis Mak, 13, 126, 10.1186/1472-6947-13-126 Takashima, 2002, Anterior distribution of stage T1c nonpalpable tumors in radical prostatectomy specimens, Urology, 59, 692, 10.1016/S0090-4295(02)01525-X Goris, 2012, Localising prostate cancer : comparison of endorectal magnetic resonance (MR) imaging and 3D-MR spectroscopic imaging with transrectal ultrasound-guided biopsy, Urol Int, 88, 12, 10.1159/000331909 Zhang, 2009, Clinical stage T1c prostate cancer : evaluation with endorectal MR imaging and MR spectroscopic imaging, Radiology, 253, 425, 10.1148/radiol.2532081390 Adamy, 2011, Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancer, J Urol, 185, 477 Klotz, 2009, Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer, J Clin Oncol, 28, 126, 10.1200/JCO.2009.24.2180 Caso, 2010, Pathological T2 sub-divisions as a prognostic factor in the biochemical recurrence of prostate cancer, BJU Int, 106, 1623, 10.1111/j.1464-410X.2010.09439.x Hashimoto, 2012, Biochemical outcome of small-volume or insignificant prostate cancer treated with radical prostatectomy in Japanese population, Int J Clin Oncol, 17, 119, 10.1007/s10147-011-0267-6 Birkhahn, 2011, Long-term outcome in patients with a Gleason score ≤6 prostate cancer treated by radical prostatectomy, BJU Int, 108, 660 Sengupta, 2008, After radical retropubic prostatectomy ‘insignificant’ prostate cancer has a risk of progression similar to low-risk ‘significant’ cancer, BJU Int, 101, 170, 10.1111/j.1464-410X.2007.07270.x Armatys, 2005, Is it necessary to separate clinical stage T1c from T2 prostate adenocarcinoma?, BJU Int, 96, 777, 10.1111/j.1464-410X.2005.05713.x Rose, 2014, Maximum tumor diameter and the risk of prostate-specific antigen recurrence after radical prostatectomy, Clin Genitourin Cancer, 10.1016/j.clgc.2014.03.008 Gretzer, 2002, Substratification of stage T1c prostate cancer based on the probability of biochemical recurrence, Urology, 60, 1034, 10.1016/S0090-4295(02)01997-0 Tosoian, 2013, Pathological outcomes in men with low risk and very low risk prostate cancer : implications on the practice of active surveillance, J Urol, 190, 1218 Albertsen, 2005, 20-year outcomes following conservative management of clinically localized prostate cancer, JAMA, 293, 2095, 10.1001/jama.293.17.2095 Bill-Axelson, 2014, Radical prostatectomy or watchful waiting in early prostate cancer, N Engl J Med, 370, 932, 10.1056/NEJMoa1311593 Aizer, 2014, Initial management of prostate-specific antigen-detected, low-risk prostate cancer and the risk of death from prostate cancer, BJU Int, 113, 43, 10.1111/j.1464-410X.2012.11789.x Liu, 2013, Androgen-deprivation therapy versus radical prostatectomy as monotherapy among clinically localized prostate cancer patients, Onco Targets Ther, 6, 725, 10.2147/OTT.S44144 O'Brien, 2011, Delay of surgery in men with low risk prostate cancer, J Urol, 185, 2143